期刊
DALTON TRANSACTIONS
卷 45, 期 33, 页码 12992-13004出版社
ROYAL SOC CHEMISTRY
DOI: 10.1039/c6dt01738j
关键词
-
资金
- Department of Defense for a Prostate Cancer Idea award [W81XWH-12-1-0406]
- American Heart Association for a National Scientist Award [14SDG18690009]
- National Heart, Lung, and Blood Institute of National Institutes of Health (NIH) [R56HL121392]
- National Institute of Neurological Disorders and Stroke of NIH [R01NS093314]
- Georgia Research Alliance
Anticancer platinum (Pt) complexes have long been considered to be one of the biggest success stories in the history of medicinal inorganic chemistry. Yet there remains the hunt for the magic bullet which can satisfy the requirements of an effective chemotherapeutic drug formulation. Pt(IV) complexes are kinetically more inert than the Pt(II) congeners and offer the opportunity to append additional functional groups/ligands for prodrug activation, tumor targeting, or drug delivery. The ultimate aim of functionalization is to enhance the tumor selective action and attenuate systemic toxicity of the drugs. Moreover, an increase in cellular accumulation to surmount the resistance of the tumor against the drugs is also of paramount importance in drug development and discovery. In this review, we will address the attempts made in our lab to develop Pt(IV) prodrugs that can be activated and delivered using targeted nanotechnology-based delivery platforms.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据